medRxiv. 2020 Nov 16. pii: 2020.11.13.20231373. [Epub ahead of print]
Morgan L Sherer,
Jun Lei,
Patrick Creisher,
Minyoung Jang,
Ramya Reddy,
Kristin Voegtline,
Sarah Olson,
Kirsten Littlefield,
Han-Sol Park,
Rebecca L Ursin,
Abhinaya Ganesan,
Theresa Boyer,
Diane M Brown,
Samantha N Walch,
Annukka A R Antar,
Yukari C Manabe,
Kimberly Jones-Beatty,
William Christopher Golden,
Andrew J Satin,
Jeanne S Sheffield,
Andrew Pekosz,
Sabra L Klein,
Irina Burd.
Importance: The effects of SARS-CoV-2 infection on immune responses during pregnancy have not been systematically evaluated.
Objective: To assess the impact of SARS-CoV-2 infection during pregnancy on inflammatory and humoral responses in maternal and fetal samples and compare antibody responses to SARS-CoV-2 among pregnant and non-pregnant women.
Design: Immune responses to SARS-CoV-2 were analyzed using samples from pregnant and non-pregnant women who had either tested positive or negative for SARS-CoV-2. We measured, proinflammatory and placental cytokine mRNAs, neonatal Fc receptor (FcRn) receptor expression, and tetanus antibody transfer in maternal and cord blood samples. Additionally, we measured anti-spike (S) IgG, anti-S-receptor binding domain (RBD) IgG, and neutralizing antibody (nAb) responses to SARS-CoV-2 in serum or plasma collected from non-pregnant women, pregnant women, and cord blood.
Setting: Johns Hopkins Hospital (JHH).
Participants: Pregnant women were recruited through JHH outpatient obstetric clinics and the JHH Labor & Delivery unit. Non-pregnant women were recruited after receiving outpatient SARS-CoV-2 testing within Johns Hopkins Health System, USA. Adult non-pregnant women with positive RT-PCR results for SARS-CoV-2, within the age range of 18-48 years, were included in the study.
Exposures: SARS-CoV-2.
Main Outcomes and Measures: Participant demographic characteristics, antibody titers, cytokine mRNA expression, and FcRn receptor expression.
Results: SARS-COV-2 positive pregnant women expressed more IL1β , but not IL6 , in blood samples collected within 14 days versus > 14 days after a confirmed SARS-CoV-2 test, with similar patterns observed in the fetal side of placentas, particularly among asymptomatic pregnant women. Pregnant women with confirmed SARS-CoV-2 infection also had reduced anti-S-RBD IgG titers and were less likely to have detectable nAb as compared with non-pregnant women. Although SARS-CoV-2 infection did not disrupt FcRn expression in the placenta, maternal transfer of nAb was inhibited by SARS-CoV-2 infection during pregnancy.
Conclusions and Relevance: SARS-CoV-2 infection during pregnancy was characterized by placental inflammation and reduced antiviral antibody responses, which may impact the efficacy of COVID-19 therapeutics in pregnancy. The long-term implications of placental inflammation for neonatal health also requires greater consideration.